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Abstract 
Background: Sympathetic activation and renin-angiotensin system are essential for development and sustenance 
of hypertension. However, the status of these systems has not been well evaluated among patients in an African set-
ting. This study therefore set out to assess the angiotensin II status and sympathetic activation among hypertensive 
patients in Uganda.
Methods: In this cross sectional study conducted at Mulago, the national referral hospital, blood samples were taken 
to measure angiotensin II, metanephrines and normetanephrines. Urine samples were also taken for measuring urine 
creatinine and sodium. The angiotensin II categories were defined using the Mosby’s Diagnostic and Laboratory Test 
References. 9th ed while the metanephrines and normetanephrine categories were defined using the Makerere Uni-
versity Biosafety II Immunology Laboratory reference values.
Results: 162 patients were consented and enrolled into the study, of these 136 (84 %) had low, 15 (9 %) had normal, 
while, 11 (7 %) had high angiotensin II levels. 142 (88 %) participants had normal levels of metanephrine, while 20 
(12 %) had high levels. Only 88 were assessed for metanephrines and of these 85 (97 %) had normal, while 3 (3 %) had 
raised levels. Urine sodium was associated with low and normal angiotensin II levels (P value 0.007). Female gender 
and diastolic blood pressure were associated with a protective effect against high normetanephrines (OR 0.29, P value 
0.015), 80–89 mmHg (OR 0.19, p value 0.053), above 100 mmHg (OR 0.27, p value 0.022). Current smoking status was 
associated with high risk for abnormal normetanephrines (OR 17.6, P value −0.022) while former smoking was associ-
ated with high risk for abnormal metanephrines (OR 18.7, p value 0.022). After multivariate analysis, all the significant 
variables at bivariate analysis were still significant except those who stopped smoking and those with a BP at 80–89 
which were not significant.
Conclusions: Hypertensive patients in this setting have predominantly low angiotensin II hypertension as a result of 
high salt intake. Sympathetic activation is not a significant mechanism of hypertension in this study population, more 
so in the females, with the exception of smokers who have a highly activated sympathetic system. Therefore, the use 
of agents targeting renin angiotensin and sympathetic systems as single first line antihypertensive agents in this set-
ting should be re-evaluated if such patients are to be treated effectively.
Keywords: Angiotensin II status, Sympathetic nervous activity, Hypertension
© 2015 Mayito et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  jmayito2011@hotmail.com 
1 Department of Medicine, College of Health Sciences, Makerere 
University, P.O. Box 7072, Kampala, Uganda
Full list of author information is available at the end of the article
Page 2 of 9Mayito et al. BMC Res Notes  (2015) 8:586 
Background
Hypertension is one of the most prevalent and major 
contributors to atherosclerotic cerebral and cardiovas-
cular disease, increasing the risk by two to threefold [1]. 
Treatment of hypertension is associated with decline 
in the risk of stroke (30–40  %), coronary artery disease 
(20 %) and other major cardiovascular diseases (21–28 %) 
[2].
Hypertension is a result of the interaction between 
genetic and environmental factors. This interaction influ-
ences intermediary phenotypes such as sympathetic 
nervous activity, renin angiotensin aldosterone, renin-
kallikrein—kinin systems, and endothelial factors [3]. 
These phenotypes in turn influence other intermediary 
phenotypes such as sodium excretion, vascular reactivity, 
and cardiac contractility, which, determine total vascular 
resistance and cardiac output, and therefore blood pres-
sure [3].
More than 70  % of hypertensive patients have renin 
related mechanisms as the aetiology of their hyperten-
sion. About 20  % of these have inappropriately normal 
or high renin values, and 30  % have low renin values, 
with the remaining half distributed between these two 
extremes [4]. Angiotensin II on the other hand has been 
shown to cause hypertension and vasculopathy through 
the activation of the mitogen-activated protein (MAP) 
kinase activity which mediates vascular smooth muscle 
proliferation [5] The effects of angiotensin II are com-
partmentalised mainly in the medulla and tubule of the 
kidney, where it regulates medulla and tubular function 
through its type 1 receptor [6]. The Na+/H+ exchanger 
3 in the proximal tubule is also key in maintaining basal 
blood pressure and the development of angiotensin II 
hypertension [7], a phenomena that should be of interest 
in blacks that predominantly have salt sensitive and low 
renin hypertension compared to the white population [8].
Sympathetic neural mechanisms are also important in 
the development and progression of hypertension. The 
magnitude of sympathetic activation is proportional to 
the degree of elevation in blood pressure and develop-
ment of hypertension-related target organ damage [9]. 
It has been suggested that repeated stress-induced sym-
pathetic activation contributes to the pathophysiology of 
hypertension in blacks unlike in white populations [10, 
11]. Increased serum and urinary metanephrines and 
normetanephrines are a measure of sympathetic activa-
tion and are used in the diagnosis of pheochromocytoma 
[12, 13].
Much has been studied about the renin angiotensin 
and sympathetic nervous systems’ role in the patho-
physiology of hypertension. Despite this, data on this 
subject in an African setting is limited. The closest data 
often cited for black populations is from the African 
Americans who may be genetically and environmentally 
distinct from blacks in an African setting. There is a need 
to fill this knowledge gap with data from an appropriate 
population. We therefore set out to assess the angioten-
sin II status and sympathetic activation of hypertensive 
patients in Uganda attending the national referral hos-
pital. Such information is extremely useful, especially in 
our low resource settings, where appropriate treatment 
of chronic conditions, basing on scientific evidence, is 
prudent. We also sought to seek for any factors associ-
ated with the prevailing status of these parameters.
Methods
This was a cross sectional study conducted at Mulago, the 
only National referral hospital in Uganda.
All study participants were recruited from the Mulago 
Hospital hypertension clinic. We recruited both newly 
diagnosed adult hypertensive patients (with no his-
tory of antihypertensive medication) and previously 
treated hypertensive patients but who had defaulted 
their medication for at least 1  week. Exclusion criteria 
included; pregnant women, patients currently or within 
1  week of using oral contraceptive therapy or adrena-
line, patients with deranged renal function tests and uri-
nalysis, patients with diabetes mellitus and confirmed 
pheochromocytoma.
A formula by Eng [14] was used to estimate the sample 
size. A total of 162 respondents were computed basing 
on 95 % confidence interval, a precision of 5 and 10 % of 
the sample size used to compensate for non-respondents.
The study participants were consecutively recruited 
from the waiting area in the hypertension clinic and 
screened using the study eligibility criteria. Those eligible 
were informed about the study and requested to give a 
written informed consent to participate in the study.
Study participants responded to a pre-coded, pre-
tested and standardized questionnaire which covered 
demographic details, duration of hypertension, duration 
off antihypertensives, type of antihypertensives that were 
being taken before defaulting, alcohol consumption, salt 
intake and smoking. They then underwent measurement 
of height, weight and blood pressure, and then gave an 
arterial blood and urine sample as elaborated below.
The body mass index (BMI) was calculated using the 
formula; weight (kg)/height (m2) and then categorized 
into underweight (<18.5), Normal weight (18.5–24.9), 
overweight (25–29.9) and obese (>30) using the world 
health organisation criteria of categorization of BMI, 
2004 [15].
The blood pressure was measured on the left arm after 
the subject had sat for at least 10 min, using an Omron 
M7 (HEM-780-E) oscillometric blood pressure monitor-
ing sphygmomanometer with the subject in the sitting 
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position, legs uncrossed, the arm resting on a table and 
the ante-cubital fossa at the level of the lower sternum. 
The Omron M7 (HEM-780-E) is validated according to 
the British hypertension Society protocol and is recom-
mended for professional and home use [16].
An appropriate cuff (with bladder length >80 % of the 
arm circumference) was used. Two readings were taken 
3  min apart and the average was used to describe the 
blood pressure of the patient. If the readings differed by 
10 mmHg, a third reading was taken and the blood pres-
sure was then taken to be the average of the closest two. 
Blood pressure was then categorized using the JNC 7 
[17].
The participant was laid on the examination couch in 
supine position for at least 15 min before the blood sam-
ple was drawn. Using a 10 ml syringe and observing asep-
tic conditions, 6 ml of blood was drawn from the femoral 
artery. Pressure was applied to the puncture site for 7 min 
to stop any bleeding. Four ml was introduced into an iced 
pre-labelled EDTA vacutainer, mixed gently by tilting the 
vacutainer top to bottom and vice versa eight times to 
mix the blood with the anticoagulant.
The sample was kept under ice in an ice box carrier 
immediately. It was then transported within 1  h to the 
laboratory where it was centrifuged at 4500 rotations 
per minute at 4 °C for 5 min to separate the plasma. The 
plasma was stored at −80  °C till analysis.  The remain-
ing ml were used for determination of plasma creatinine 
and sodium at the Mulago Hospital clinical chemistry 
laboratory.
All the samples were analysed within 5  months 
from the time of collection at the Makerere University 
Biosafety II Immunology Laboratory, using the Assay-
Max Human Angiotensin II Elisa Kit from ASSAYPRO, 
Germany and 2-MET Plasma Elisa fast track from Labor 
Diagnostic Nord, Germany.
The Mosby’s Diagnostic and Laboratory Test Refer-
ences. 9th ed angiotensin II reference ranges (0.01–
0.06  ng/ml) and the Makerere University Biosafety 
II Immunology Laboratory reference values for 
metanephrine (<90  pg/ml) and normetanephrine 
(<180  pg/ml) were used to categorise these measure-
ments into low, normal, and high [18, 19].
Patients were instructed to collect a mid-stream urine 
sample after washing with soap the head of the penis and 
the retracted foreskin (for men) or the separated skin 
folds covering the urinary opening (for females). The 
urine sample was transported within 1  h to the labora-
tory for determination of urine sodium and creatinine.
Data analysis
Data analysis was done with the assistance of a statisti-
cian. Data were double entered using EPI-INFO 6.0 and 
then exported to STATA version 12.0 (StataIC Corpora-
tion, College Station, TX, USA) for analysis.
The independent variables which included: social 
demographics, alcohol intake, smoking history, salt 
intake, treatment history of hypertension, physical meas-
urements, and fraction excretion of sodium were organ-
ised into categories. The outcomes of interest in this 
study were percentages and their confidence intervals of 
the participants with low, moderate and high angiotensin 
II, metanephrine and normetanephrines levels.
Logistics regression model was used to assess for fac-
tors associated with the three parameters outcomes by 
estimating the odds ratio and accompanying 95 % confi-
dence interval. Only variables that were significant in the 
bivariate analysis (gender, smoking and diastolic BP) were 
considered for multivariate analysis, and a forward fitting 
regression model was used to assess for effect modifica-
tion and confounders. In all analyses, a P value of ≤0.05 
was considered to be statistically significant.
Supporting data
The full dataset for this study is available on Zenodo data 
repository. DOI 10.5281/Zenodo.31479.
Ethical approval
Written informed consent was obtained from all study 
participants. The study protocol was approved by the 
Makerere University School of Medicine Research and 
Ethics Committee, and Uganda National Council of Sci-
ence and Technology.
Results
162 Patients were recruited for the study as shown in 
Fig.  1. Majority of the participants were female, 131 
(81  %), and Baganda were the most represented ethnic 
group, 116 (71.6 %).
There were more senior citizens, 122 (75  %), above 
45 years and 61 (38 %) above 60 years with hypertension 
compared to the younger participants 40 (25  %) below 
45 years and 6 (4 %) participants below 30 years (Table 1).
Sixty-seven (42  %) of the participant added raw salt 
to their food. Among the 162 participants, majority 64 
(40  %) of them added one table spoon to their food as 
they prepared it, closely followed by 54 (33 %) who added 
half a table spoon.
Majority of the participants, 136 (84  %) had normal 
pulse rates and majority had a systolic blood pressure of 
more than 160 mmHg and a diastolic blood pressure of 
more than 100 mmHg, 108 (67 %) and 89 (55 %) respec-
tively. Twenty-nine (18  %) participants had grade one 
obesity while 9 (6 %) were morbidly obese. See Table 2.
Sixteen (10  %) participants were recently diagnosed 
with hypertension compared to 146 (90  %) who had a 
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known diagnosis of hypertension but had defaulted tak-
ing their medications. Among the 146 previously treated 
defaulting participants, 34 (23  %) of them had been on 
single drug therapy while 112 (77 %) had been on com-
bination therapy. The most commonly used class of sin-
gle drug therapy was calcium channel blockers, 13 (38 %) 
while the most commonly used combination therapy was 
a diuretic with a calcium channel blocker and either an 
ACEI or ARB 27 (24 %). See Table 3.
The smoking rates in this study were very low, with 3 
(1.9 %) and 12 (7 %) being current and former smokers 
respectively. The participants currently taking alcohol 
were 35 (22 %). Among the 35 participants, 18 (51 %) 
were taking beer, followed by local gin (waragi) at 12 
(34 %). Among the 31 who took quantifiable amounts 
of alcohol, the majority took 1–6 bottles of beer per 
week while only one participant took a glass of wine 
daily.
Renin angiotensin status
Eighty-four percent (136) of the participants had low 
angiotensin II levels. This represented a proportion of 
78–90  % of the reference population as shown by the 
95  % confidence interval. Among the participants with 
low angiotensin II levels, 130 (97 %) had normal, 4 (3 %) 
had low while none had high urine excretion of sodium. 
In contrast however, majority with low angiotensin II lev-
els, 120 (90  %), had a fractional excretion of sodium of 
less than 1 %. Urine sodium was the only factor signifi-
cantly associated with low and normal angiotensin II lev-
els, P value = 0.007 as illustrated in Table 4.
Sympathetic nervous activity
Majority of the participants, 142 (88 %) had normal nor-
metanephrine levels representing a range of 83–93  % 
in the reference population as shown by the 95  % con-
fidence intervals. A similar proportion, 85 of the 88 
335 were excluded 
330 were on anhypertensives 
5 had deranged Renal funcon tests 
162 enrolled, quesonnaires administered, 
Physical measurements, blood & urine samples 
taken 
162 had all Angiotensin II & 
Normetanephrine results 
RAAS status & sympathec acvity 
determined using angiotensin II, 
metanephrines &normetanephrines levels 
500 aended the Hypertensive clinic during the 
study period & were screened 
165 were eligible for enrolment 
3 did not give informed consent 
Factors associated with 
Angiotensin II &sympathec 
acvity determined
74 lacked metanephrine 
results from the 
laboratory 
Fig. 1 Flow chart for participants’ selection
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(97  %) participants with metanephrine results had nor-
mal metanephrine levels representing 92–100  % of the 
reference population as shown by the 95  % confidence 
intervals.
Among the participants with normal metanephrines, 
60 (71  %) had a systolic blood pressure of more than 
160 mmHg compared to 94 (66 %) with normal norme-
tanephrines. The percentage of participants with normal 
metanephrines and normetanephrines who had a dias-
tolic blood pressure of more than 100 mmHg was similar, 
55 and 56 % respectively.
Distribution by the other variable is shown in Table 5.
Being female was associated with a significant pro-
tective effect from high normetanephrine OR 0.29 
(0.11–0.79), P =  0.015 and so was diastolic blood pres-
sure of 80–89  mmHg OR 0.19 (0.03–1.02), p  =  0.053, 




 ≤45 40 25
 >45 122 75
Age distribution
 18–40 25 15
 41–60 76 47
 >60 61 38
Gender
 Male 31 19
 Female 131 81
Tribe
 Buganda 116 72
 Basoga 7 4
 Banyankole 13 8
 Banyoro 5 3
 Others 21 23
Occupation
 Peasant/farmer 69 43
 Manual labourer 50 31
 Office worker 7 4
 Unemployed 36 22
Level of education
 No formal 22 14
 Primary 96 59
 Secondary 37 23
 Tertiary 7 4
Marital status
 Single 11 7
 Married 80 49
 Divorced/separated 71 44




 <60 8 5
 61–100 136 84
 >100 18 11
Systolic blood pressure
 <120 3 2
 120–139 12 7
 140–159 39 24
 >160 108 67
Diastolic blood pressure
 <80 22 14
 80–89 25 15
 90–99 26 16
 ≥100 89 55
BMI
 <18.5 9 6
 18.5–24.9 63 39
 25–29.9 51 32
 30–34.9 29 18
 >35 9 6




 1 week 50 34
 1 to <2 weeks 42 29
 2 to ≤4 weeks 17 12
 1 month 13 9
 >1 month 22 15
 No record 2 1
Single drug antihypertensives
 Duiretic 2 6
 Calcium channel blocker 13 38
 Beta blocker 8 24
 ACEI/ARBs 9 26
 Others 1 3
 No record 1 3
Combination drug antihypertensive
 Duiretic and Calcium Ch. 13 12
 Duiretic and ACEI/ARB 5 4
 Calcium Ch and beta blocker 10 9
 Calcium Ch. and ACEI/ARB 19 17
 Beta block + ACEI/ARBs 6 5
 Duiretic + calcium ch + ACEI/ARB 27 24
 Others 27 24
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90–99  mmHg OR 0.86 (0.01–0.77), P  =  0.028 and 
>100 mmHg OR 0.27 (0.83–0.89, p = 0.022, as shown in 
Table 6.
Current smoking status was associated with a signifi-
cantly increased risk of abnormal normetanephrine lev-
els OR 17.6 (1.50–205.820), P value −0.022, while former 
smoking status was associated with increased risk of ele-
vated metanephrines OR 18.75 (1.53–230.42), P = 0.022, 
as shown in Table 6.
After multivariate analysis, all the significant variables 
at bivariate analysis were still significant except those 
who stopped smoking and those with a BP at 80–89 
which were not significant (Table 7).
Discussion
The major finding in this study was that majority of the 
participants had low angiotensin II levels, which, corre-
lated with the finding that majority of participants had a 
fractional excretion of sodium of less than 1 %. This clini-
cal state is similar to patients with pre-renal azotemia 
whereby they are highly conserving sodium and water 
leading to a high effective circulatory volume. It is pos-
sible that high salt intake in this population suppresses 
angiotensin II release as majority of the participants 
reported taking salt in their diet, especially raw salt and 
urine sodium was associated with low angiotensin II lev-
els. It would have been important to correlate the angio-
tensin II levels with renin levels as previous studies have 
shown majority of blacks to have a low renin hyperten-
sion [8] as a result of negative feedback from angioten-
sin II in a form of apparent minero-corticoid excess [20]. 
A full evaluation of the renin aldosterone angiotensin 
axis would have enabled more concrete conclusions. 
The fact that blacks are more responsive to diuretics 
and that addition of a diuretic improves efficacy of other 
antihypertensives in black populations unlike in white 
Table 4 Bivariate for  angiotensin II levels and  associated 
factors
Risk factor Angiotensin II categories
<0.01 (low) 0.01–0.06 
(normal)
>0.06 (high) P value
Number (%) Number (%) Number (%)
Age in years
 ≤45 32 (23.53) 6 (40.00) 2 (18.18) 0.326
 >45 104 (76.47) 9 (60.00) 9 (81.82)
Gender
 Male 25 (18.38) 5 (33.33) 1 (9.09) 0.257
 Female 111 (81.62) 10 (66.67) 10 (90.91)
Smoking
 No 2 (1.47) 0 1 (9.09) 0.111
 Stopped 126 (92.65) 12 (80.00) 9 (81.82)
 Yes 8 (5.88) 3 (20.00) 1 (9.09)
Alcohol
 Yes 30 (22.22) 2 (13.33) 3 (27.27) 0.657
 No 105 (77.78) 13 (86.67) 13 (86.67)
Systolic BP
 <120 3 (2.21) 0 0 0.930
 120–139 10 (7.35) 1 (6.67) 1 (9.09)
 140–159 34 (25.00) 2 (13.33) 3 (27.27)
 >160 89 (65.44) 12 (80.00) 7 (63.64)
Diastolic BP
 <80 22 (16.18) 0 0 0.221
 80–89 19 (13.97) 4 (26.67) 2 (18.18)
 90–99 24 (17.65) 1 (6.67) 1 (9.09)
 ≥100 71 (52.21) 10 (66.67) 8 (72.73)
Pulse rate
 <60 8 (5.88) 0 0 0.373
 61–100 112 (82.35) 15 (100) 9 (81.82)
 >100 16 (11.76) 0 2 (18.18)
Salt intake
 Yes 56 (41.18) 7 (46.67) 4 (36.36) 0.865
 No 80 (58.82) 8 (53.33) 7 (63.64)
Urine sodium (mmol/l)
 <20 4(2.99) 3 (20.00) 0 0.007
 20–350 130 (97.01) 12 (80.00) 11 (100)
FENa
 <1 120 (89.55) 14 (93.33) 7 (70.00) 0.059
 1–2 9 (6.72) 0 3 (30.00)
 >2 5 (3.73) 1 (6.67) 0
Time since diagnosis
 <1 month 11 (8.09) 3 (20.00) 2 (18.18) 0.697
 1 to 
<6 months
8 (5.88) 1 (6.67) 0
 6 to 
<12 months
9 (6.62) 1 (6.67) 1 (9.09)
 >1 year 108 (79.41) 10 (66.67) 8 (72.73)
Table 4 continued
Risk factor Angiotensin II categories
<0.01 (low) 0.01–0.06 
(normal)
>0.06 (high) P value
Number (%) Number (%) Number (%)
Time off antihypertensives
 1 week 45 (36.59) 2 (15.38) 3 (37.50) 0.360
 1 to <2 weeks 34 (27.64) 7 (53.35) 1 (12.50)
 2 to ≤4 weeks 14 (11.38) 1 (7.69) 2 (25.00)
 1 month 11 (8.94) 2 (15.38) 0
 >1 month 19 (15.45) 1 (7.69) 2 (25.00)
FENa fraction excretion of urine sodium
The P values in italics indicate factors associated with angiotensin II at α = 0.05
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populations [21], further shows that salt plays a major 
role in the mechanism of hypertension in blacks. Other 
syndromes associated with conservation of sodium and 
water include; increased endothelin-1 activity [22] or a 
mutation in the epithelial sodium receptor (ENaC) [23] 
and these would require further evaluation in this study.
Findings from this study suggest that sympathetic nervous 
activation may not be a dominant mechanism in the patho-
physiology of hypertension in this study population. This 
is in contrast to previous studies that have shown increased 
sympathetic nervous out flow in patients with accelerated 
or malignant hypertension, where, the sympathetic out flow 
is due to the increased endogenous renin-angiotensin axis 
which stimulates it at the sympathetic ganglia [24] and cen-
trally [25]. These findings are also at variance with the sug-
gestions that repeated stress-induced sympathetic activation 
initiates a cycle of increased vascular resistance and vascular 
hypertrophy leading to hypertension in black populations [10, 
11]. We however, acknowledge that the smaller number of 
samples analysed for metanephrines could have under pow-
ered this study for making conclusions about the sympathetic 
activity. These results support the fact that beta blockers are 
not effective first line antihypertensive therapy, especially in 
black population and should therefore be reserved for com-
pelling situations or improved by addition of a diuretic [26]. 
Furthermore, female gender was associated with a protective 
effect against high normetanephrines. This finding concurs 
with earlier findings which showed that autonomic blood 
pressure support is blunted in females more so in young 
women [27]. This attenuation of the sympathetic nervous sys-
tem in females may be due to dampened sympatho-adrenal 
stimulation or augmented sympatho-adrenal inhibition [28].
More to the above, current smoking status was asso-
ciated with increased stimulation of the sympathetic 
nervous activation meaning that smoking may be a con-
tributing mechanism to developing hypertension in 
smokers. This finding is similar to results of other studies 
which showed that smoking has a direct peripheral and 
a centrally mediated effect on both blood pressure and 
pulse through stimulation of the sympathetic nervous 
system [29]. However, we acknowledge that the number 
of smokers was very low and this could have led to an 
over effect in assessing the associations.
It was also seen in this study that increase in diastolic 
blood pressure showed dampening or protection against 
increased sympathetic nervous activity. The diastolic 
blood pressure is related to relaxation of the cardiac mus-
cle which occurs with reduced sympathetic outflow and 
sustained by residual pressure retained by the elasticity 
of the arterial system [30]. The sympathetic nervous sys-
tem may therefore not play a significant role in diastolic 
hypertension in this study population.
Conclusions
Hypertensive patients in this setting have predominantly 
low angiotensin II hypertension as a result of high salt 
Table 5 Distribution of metanephrines and normetanephrines by different variables
Characteristic Metanephrines Normetanephrines
Normal, N = 85 (%) High, N = 3 (%) Normal, N = 142 (%) High, 20 (12 %)
Gender
 Male 21 (25) 2 (67) 23 (16) 8 (40)
 Females 64 (75) 1 (33) 119 (84) 12 (60)
Age
 <45 24 (28) 2 (67) 36 (25) 4 (25)
 ≥45 61 (72) 1 (33) 106 (75) 16 (75)
Systolic BP
 <140 5 (6) 0 14 (10) 1 (5)
 140–160 20 (24) 1 (33) 34 (24) 5 (25)
 >160 60 (71) 2 (67) 94 (66) 14 (70)
Diastolic BP
 <90 23 (27) 1 (33) 38 (27) 9 (45)
 90–100 7 (8) 0 25 (18) 1 (5)
 >100 55 (65) 2 (67) 79 (56) 10 (50)
Pulse
 <60 6 (7) 7 (5) 1 (5)
 60–100 67 (79) 119 (84) 17 (85)
 >100 12 (14) 16 (11) 2 (10)
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Table 6 Bivariate analysis for factors associated with metanephrines and normetanephrines
FENa fractional excretion of sodium. Logistic regression model was used to determine the differences between the metanephrine and normetanephrine categories
The p values in italics indicate factors associated with metanephrines and normetanephrines at α = 0.05
Risk factor Metanephrines Normetanephrines
Odds (95 % CI) OR (95 % CI) p value Odds (95 % CI) OR (95 % CI) p value
Age in years
 ≤45 0.08 (0.02–0.35) 0.11 (0.04–0.31)
 >45 0.02 (0.00–0.12) 0.20 (0.02–2.37) 0.154 0.15 (0.08–0.26) 1.4 (0.43–4.33) 0.604
Gender
 Male 0.10 (0.02–0.41) 0.35 (0.16–0.78)
 Female 0.02 (0.00–0.11) 0.16 (0.01–2.00) 0.106 0.10 (0.06–0.18) 0.29 (0.11–0.79) 0.015
Smoking
 No 0.01 (0.00–0.10) Reference 0.11 (0.07–0.19) Reference
 Stopped 0.25 (0.05–1.18) 18.75 (1.53–230.42) 0.022 0.33 (0.09–1.23) 2.93 (0.72–12.03) 0.135
 Yes 0 – – 2.00 (0.18–22.06) 17.6 (1.50–205.82) 0.022
Alcohol
 Yes 0.11 (0.03–0.48) 0.21 (0.09–0.50)
 No 0.02 (0.00–0.11) 0.14 (0.01–1.69) 0.069 0.13 (0.07–0.22) 0.60 (0.21–1.71) 0.342
Systolic BP
 <120 0 0.50 (0.05–5.51) Reference
 120–139 0 0 – –
 140–159 0.05 (0.01–0.37) Reference 0.15 (0.06–0.38) 0.29 (0.02–3.87) 0.352
 >160 0.03 (0.01–0.14) 0.67 (0.06–7.88) 0.746 0.15 (0.08–0.26) 0.30 (0.03–3.50) 0.336
Diastolic BP
 <80 0.10 (0.01–0.78) Reference 0.47 (0.19–1.14) Reference
 80–89 – – – 0.087 (0.02–0.37) 0.19 (0.03–1.02) 0.053
 90–99 – – – 0.04 (0.01–0.30) 0.86 (0.01–0.77) 0.028
 ≥100 0.04 (0.01–0.15) 0.36 (0.03–4.40) 0.426 0.12 (0.07–0.24) 0.27 (0.89–0.83) 0.022
Pulse rate
 <60 0 – – 0.14 (0.02–1.16) Reference
 61–100 0.04 (0.01–0.14) – – 0.14 (0.09–0.24) 1 (0.12–8.64) 1.00
 >100 0 – – 0.13 (0.03–0.54) 0.88 (0.07–11.31) 0.919
Salt intake
 Yes 0.07 (0.02–0.29) 0.16 (0.08–0.31)
 No 0.02 (0.00–0.13) 0.26 (0.02–3.08) 0.249 0.07 (0.07–0.25) 0.84 (0.33–2.17) 0.724
FENa
 <1 0.04 (0.01–0.13) 0.13 (0.08–0.22) Reference
 1–2 0 – – 0.20 (0.04–0.91) 1.56 (0.31–7.77) 0.586
 >2 0 – – 0.20 (0.02–1.71) 1.56 (0.17–14.23) 0.692
Time since diagnosis
 <1 month 0 Reference 0.07 (0.01–0.50) Reference
 1 to <6 months 0.17 (0.02–1.38) 0.86 (0.04–18.73) 0.922 0.50 (0.13–2.00) 7.50 (0.65–87.19) 0.107
 6 to <12 months 0.14 (0.01–1.16) 0.10 (0.00–1.97) 0.060 0.22 (0.05–1.03) 3.33 (0.26–42.21) 0.353
 >1 year 0.02 (0.00–0.12) 0.13 (0.07–0.22) 1.88 (0.23–15.30) 0.557
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intake. Sympathetic nervous activation is not a significant 
mechanism of hypertension in patients in this setting, 
more so in the females, but may be exaggerated in cur-
rent smokers. Use of agents targeting renin angiotensin 
and sympathetic systems as single first line antihyper-
tensive agents in this setting needs to be re-evaluated for 
better management of patients in this setting.
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